MedTrace Logo

Montelukast as a Controller of Atopic Syndrome

NCT00559546 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2007-11-16

No results posted yet for this study

Summary

The purpose of the study is to find out if montelukast can be used to treat the various symptoms of allergic syndrome.

Conditions

  • Seasonal Allergic Rhinitis
  • Allergic Conjunctivitis
  • Atopic Eczema
  • Asthma

Interventions

DRUG

montelukast

10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner

Sponsors & Collaborators

Principal Investigators

  • Tari Haahtela, Professor · Skin and Allergy Hospital, Helsinki University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Completion
2007-07-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559546 on ClinicalTrials.gov